Polymyxin B-Induced Skin Hyperpigmentation

Polymyxin B-induced skin hyperpigmentation is a rare adverse drug reaction (ADR). In this report, we present the case of a patient who underwent an abscess resection with right epididymitis, in which a multidrug-resistant Klebsiella pneumoniae infection (KPI) is formed. The patient was treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Xueke, Luo, Chunliu, Lyu, Weitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519980/
https://www.ncbi.nlm.nih.gov/pubmed/33014066
http://dx.doi.org/10.1155/2020/6461329
_version_ 1783587684936056832
author Wen, Xueke
Luo, Chunliu
Lyu, Weitao
author_facet Wen, Xueke
Luo, Chunliu
Lyu, Weitao
author_sort Wen, Xueke
collection PubMed
description Polymyxin B-induced skin hyperpigmentation is a rare adverse drug reaction (ADR). In this report, we present the case of a patient who underwent an abscess resection with right epididymitis, in which a multidrug-resistant Klebsiella pneumoniae infection (KPI) is formed. The patient was treated with polymyxin B and subsequently developed skin hyperpigmentation and desquamation. The desquamation improved and the pigmentation gradually returned to normal after sixty days after the withdrawal of polymyxin B.
format Online
Article
Text
id pubmed-7519980
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75199802020-10-02 Polymyxin B-Induced Skin Hyperpigmentation Wen, Xueke Luo, Chunliu Lyu, Weitao Case Rep Med Case Report Polymyxin B-induced skin hyperpigmentation is a rare adverse drug reaction (ADR). In this report, we present the case of a patient who underwent an abscess resection with right epididymitis, in which a multidrug-resistant Klebsiella pneumoniae infection (KPI) is formed. The patient was treated with polymyxin B and subsequently developed skin hyperpigmentation and desquamation. The desquamation improved and the pigmentation gradually returned to normal after sixty days after the withdrawal of polymyxin B. Hindawi 2020-09-18 /pmc/articles/PMC7519980/ /pubmed/33014066 http://dx.doi.org/10.1155/2020/6461329 Text en Copyright © 2020 Xueke Wen et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Wen, Xueke
Luo, Chunliu
Lyu, Weitao
Polymyxin B-Induced Skin Hyperpigmentation
title Polymyxin B-Induced Skin Hyperpigmentation
title_full Polymyxin B-Induced Skin Hyperpigmentation
title_fullStr Polymyxin B-Induced Skin Hyperpigmentation
title_full_unstemmed Polymyxin B-Induced Skin Hyperpigmentation
title_short Polymyxin B-Induced Skin Hyperpigmentation
title_sort polymyxin b-induced skin hyperpigmentation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519980/
https://www.ncbi.nlm.nih.gov/pubmed/33014066
http://dx.doi.org/10.1155/2020/6461329
work_keys_str_mv AT wenxueke polymyxinbinducedskinhyperpigmentation
AT luochunliu polymyxinbinducedskinhyperpigmentation
AT lyuweitao polymyxinbinducedskinhyperpigmentation

Ejemplares similares